Teleflex Incorporated (NYSE:TFX) Expected to Announce Quarterly Sales of $631.24 Million

Brokerages forecast that Teleflex Incorporated (NYSE:TFXGet Rating) will announce $631.24 million in sales for the current quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Teleflex’s earnings. The highest sales estimate is $637.64 million and the lowest is $628.20 million. Teleflex reported sales of $633.93 million during the same quarter last year, which indicates a negative year-over-year growth rate of 0.4%. The business is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Teleflex will report full-year sales of $2.90 billion for the current fiscal year, with estimates ranging from $2.88 billion to $2.95 billion. For the next financial year, analysts expect that the company will report sales of $3.08 billion, with estimates ranging from $3.04 billion to $3.15 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Teleflex.

Teleflex (NYSE:TFXGet Rating) last announced its quarterly earnings data on Thursday, February 24th. The medical technology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.53 by $0.07. Teleflex had a net margin of 17.28% and a return on equity of 17.74%. The business had revenue of $761.90 million for the quarter, compared to the consensus estimate of $749.60 million. During the same quarter last year, the company posted $3.25 earnings per share. Teleflex’s quarterly revenue was up 7.1% on a year-over-year basis.

A number of research firms recently weighed in on TFX. Piper Sandler upped their target price on shares of Teleflex from $320.00 to $335.00 in a research note on Thursday, February 24th. started coverage on shares of Teleflex in a report on Thursday, March 31st. They set a “buy” rating for the company. Zacks Investment Research lowered shares of Teleflex from a “hold” rating to a “sell” rating and set a $373.00 price target on the stock. in a research report on Friday, April 1st. Needham & Company LLC dropped their price objective on shares of Teleflex from $425.00 to $400.00 and set a “buy” rating for the company in a report on Monday, January 31st. Finally, Morgan Stanley reduced their target price on Teleflex from $383.00 to $378.00 and set an “equal weight” rating on the stock in a report on Friday, February 25th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $397.08.

Shares of TFX stock opened at $338.10 on Thursday. The firm has a fifty day moving average of $336.44 and a 200-day moving average of $336.49. The stock has a market cap of $15.86 billion, a price-to-earnings ratio of 33.02, a P/E/G ratio of 1.90 and a beta of 1.06. Teleflex has a 52-week low of $289.00 and a 52-week high of $449.38. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 2.10.

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 15th. Stockholders of record on Monday, March 7th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.40%. The ex-dividend date was Friday, March 4th. Teleflex’s dividend payout ratio (DPR) is presently 13.28%.

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in Teleflex by 1.6% during the 4th quarter. BlackRock Inc. now owns 4,856,339 shares of the medical technology company’s stock valued at $1,595,212,000 after purchasing an additional 78,713 shares during the period. Wellington Management Group LLP raised its stake in shares of Teleflex by 2.6% during the third quarter. Wellington Management Group LLP now owns 3,263,400 shares of the medical technology company’s stock worth $1,228,833,000 after buying an additional 82,510 shares during the last quarter. State Street Corp lifted its holdings in Teleflex by 3.0% in the fourth quarter. State Street Corp now owns 1,952,123 shares of the medical technology company’s stock valued at $641,233,000 after buying an additional 56,290 shares during the period. American Century Companies Inc. boosted its stake in Teleflex by 0.9% in the third quarter. American Century Companies Inc. now owns 1,325,724 shares of the medical technology company’s stock valued at $499,201,000 after acquiring an additional 12,194 shares during the last quarter. Finally, Atlanta Capital Management Co. L L C grew its holdings in Teleflex by 108.3% during the 4th quarter. Atlanta Capital Management Co. L L C now owns 1,058,932 shares of the medical technology company’s stock worth $347,838,000 after acquiring an additional 550,512 shares during the period. Hedge funds and other institutional investors own 91.86% of the company’s stock.

Teleflex Company Profile (Get Rating)

Teleflex, Inc provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Read More

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with's FREE daily email newsletter.